My Companies
Notification
Account
Log Out
Login
Board approved investment of up to Rs 1,400 Cr in wholly-owned subsidiary Natco Pharma South Africa. Board also approved acquisition of additional stake in Adcock Ingram Holdings, increasing holding from 35.75% to 49% for ZAR 1.8 Bn (~Rs 1,069 Cr) in cash.
Natco Pharma Sets ₹1,279 Crore Rights Issue At ₹750 Per Share
Natco Pharma Fixes ₹750 Price For ₹1,279 Crore 2:21 Rights Issue
Natco Pharma Proposes ₹1,300 Crore Rights Issue For Debt Repayment
Natco Pharma Approves Rights Issue Of Up To ₹1,300 Crore
Natco Pharma Explores ₹2,000 Crore Capital Raise Alongside Q1 Results